Stryker announces publication of the DAWN(TM) Trial results in the New England Journal of Medicine

Food and Healthcare Press Releases Tuesday November 14, 2017 17:40
KALAMAZOO, Michigan, USA--14 Nov--PRNewswire/InfoQuest

The New England Journal of Medicine published the results of the DAWN Trial, the first to provide compelling evidence in treating late window and wake-up stroke patients with mechanical thrombectomy. Currently, less than one in 10 patients suffering from an ischemic stroke receives thrombectomy, due in part to a lack of scientific evidence supporting treatment beyond six hours. The results shown in the DAWN trial have the potential to fundamentally change the paradigm of care for stroke patients globally.

According to Dr. Tudor Jovin, co-principal investigator from the University of Pittsburgh Medical Center, "By quadrupling the size of the therapeutic time window, the consequence of DAWN is that many more patients with large vessel occlusion stroke have the potential to be treated with mechanical thrombectomy.   DAWN validates the physiological, rather than time-based approach to patient selection for endovascular therapy."

"Time alone should no longer be a disqualifier for thrombectomy but rather only a source of urgency.   We hope this new treatment paradigm will benefit a large proportion of patients who were previously deemed untreatable," commented Dr. Raul Nogueira, Professor of Neurology, Neurosurgery and Radiology at Emory University School of Medicine and Director of Neuroendovascular Service, Marcus Stroke & Neurosciences Center, Grady Memorial Hospital and co-principal investigator on the study.

"The results of the DAWN Trial offer the first level-one evidence of significant reduced disability in patients who present in the late time window," said Mark Paul, president of Stryker's Neurovascular division. "However, best outcomes are achieved when patients are treated as quickly as possible, requiring increased patient awareness, EMS outreach and hospital infrastructure to be in place."

The DAWN Trial reflects Stryker's commitment to clinical leadership and focus on patient pathway development. Sponsored by Stryker, the trial was designed to evaluate functional outcomes at 90 days in stroke patients treated with mechanical thrombectomy using the Trevo(R) Retriever compared to those receiving medical therapy alone. Patients were screened for inclusion in the trial if they had a stroke that started within six to 24 hours, or a stroke with an unknown time of onset—a significantly longer treatment window than the currently cleared thrombectomy indication.

About the Trevo Retriever

Stryker's Trevo Retriever is a tiny stent-shaped medical device that is attached to a thin wire. In a minimally invasive procedure that utilizes X-ray, the physician navigates the retriever from the femoral artery (located in the upper leg) to the blocked blood artery in the brain.   The retriever is designed to ensnare the blood clot and remove it from the body. Originally cleared by the FDA in 2012 for the revascularization of patients experiencing ischemic stroke, the Trevo Retriever has been used in thousands of patients worldwide. The retriever's indication within the DAWN Trial, for use in patients treated six to 24 hours after last seen well, is currently under an Investigational Device Exemption (IDE) only. The Trevo Retriever was the only mechanical thrombectomy device used in the DAWN Trial.

An animation and Important Safety Information of Stryker's Trevo Retriever is available here: https://youtu.be/PxcERzyI67I
About ischemic stroke

An ischemic stroke occurs when an artery in the brain becomes blocked by a blood clot or other substance such as plaque, a fatty material. Blood vessels carry blood, oxygen and nutrients throughout the body and to the brain. When the brain is deprived of blood and oxygen, it fails to work properly. Depending on the severity of the stroke and the area of the brain affected, loss of brain function or death may occur. According to the World Heart Federation, ischemic stroke contributes to 6 million deaths around the globe [1].

About Stryker

Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes.   More information is available at www.stryker.com .

Media contact
Keri Laden
Stryker
510 413 2534
keri.laden@stryker.com
[1] http://www.worldstrokecampaign.org/learn.html . Accessed September 19, 2017.
Logo - http://mma.prnewswire.com/media/601960/STRYKER_LOGO.jpg

Latest Press Release

Singapore National Eye Centre, Singapore Eye Research Institute And Johnson Johnson Vision Set Sights On Halting Global Myopia Epidemic

New US$26.35 Million Collaboration Seeks Prevention and Treatment Solutions to Address Rising Burden of Condition The Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI) and Johnson & Johnson Vision today announced a...

TIENS Group Launches Global Expansion Into New Retail

Leading healthcare company, TIENS Group, has announced their global expansion into the new retail market with the opening of a new flagship TIENS Experience Store in China. Located in the TIENS International Health Industrial Park, the new store features...

Medicines We Can Trust Campaign Rallies Mekong Governments and Leaders to Improve Access to Quality Medicines

Cambodian Prime Minister Hun Sen and other leaders from the Greater Mekong Subregion joined hands as part of a global campaign to improve access to quality medicines. The announcement was made during the Phnom Penh Regional Conference on the fight...

SI Group Announces New Executive Leadership

SI Group, a leading global developer and manufacturer of performance additives, process solutions, pharmaceuticals and chemical intermediates, announced today the company's new executive leadership team. These changes follow the October 15, 2018...

Grunenthal Acquires Global Rights for Qutenza(R)

Grunenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for the dermal pain patch Qutenza(R) (8% capsaicin) from Acorda Therapeutics, Inc (USA). Grunenthal is now...

Related Topics